Camsirubicin + Pegfilgrastim to Determine MTD in ASTS
← catalyst calendarSponsored by Monopar Therapeutics (industry) · MNPR — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
14actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-04
Why the sponsor stopped it
lack of timely enrollment
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-22 | actual | When the study began enrolling |
| Primary completion | 2023-10-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2024-05-13 | actual | The whole study's end, after follow-up |
| First posted | 2021-09-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-05-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Soft-tissue Sarcoma
Intervention
- Drug: Camsirubicin
Primary outcomes
what the primary-completion date above is the date OFTo determine Maximum Tolerated Dose (MTD)
measured 3 weeks after first injection
Recommended Phase 2 Dose (RP2D) Camsirubicin HCl for Injection
measured Up to 1 year after the first dose
Related
MNPR's other studiesmost recently updated first
- MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer — · Temporarily not available
- MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer — · Temporarily not available
- Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors Phase 1 · Active, not recruiting
- Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors Phase 1 · Active, not recruiting
- Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer. Phase 2/3 · Terminated
Permalink · MNPR's whole pipeline · Catalyst calendar · Every registered study · What changed